PTEN and pachyonychia congenita: PTEN loss was associated with aggressive behavior of PC (worse prognosis) and demonstrated a prognostic role in low-risk localized PC (endpoint: upgrading the biopsy grade group to higher grade on RP; may identify unsuitable low-risk patients for AS; insufficient data to be recommended in clinical practice) or RP-treated patients (endpoint: biochemical recurrence; conflicting data) and a possible predictive role in mCRPC (resistance to therapy, particularly to abiraterone) [132].